## IQV: IQVIA Holdings Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.96 indicates fundamental undervaluation. Quality metrics strong (ROE 19%). Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-3.7% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($213.83)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 5, Bearish: 0)

**1. IQVIA (IQV) Stock: Q3 2025 Results, 23% 3-Month Surge, and Analyst Outlook - News and Statistics**
- Source: IndexBox | 20251204T071117 | Bullish | Relevance: 100%
- IQVIA Holdings Inc. (IQV) is trading 3% below its 52-week high after reporting strong Q3 2025 financial results, with revenue up 5.2% and adjusted EPS up 5.6% year-over-year. The stock has surged 23.1% in the past three months, outperforming the S&P 500, and analysts have a "Strong Buy" consensus rating with a 7.4% upside potential.

**2. Is IQVIA Holdings Stock Outperforming the S&P 500?**
- Source: Markets Financial Content | 20251204T033200 | Bullish | Relevance: 100%
- IQVIA Holdings Inc. (IQV) has shown strong performance in the short term, with its stock soaring 23.1% over the past three months, outperforming the S&P 500's 6.2% gains. The company, valued at $38.4 billion, exceeded Q3 earnings expectations and boasts a "Strong Buy" consensus rating from analysts. While slightly lagging the broader market over longer periods, IQV demonstrates a bullish trend and significant upside potential.

**3. Those who invested in IQVIA Holdings (NYSE:IQV) five years ago are up 34%**
- Source: Yahoo Finance | 20251205T120916 | Neutral | Relevance: 100%
- Investors who bought IQVIA Holdings (NYSE:IQV) stock five years ago have seen a 34% increase, which is below the broader market return. While the stock has risen 12% in the last year, its share price gain of 6% annually over five years lags behind its compound earnings per share growth of 52% per year, suggesting the market has become more pessimistic about the company. The article suggests focusing on underlying fundamentals for long-term investment.

**4. M&T Bank Corp Lowers Position in IQVIA Holdings Inc. $IQV**
- Source: MarketBeat | 20251205T114746 | Neutral | Relevance: 100%
- M&T Bank Corp recently reduced its stake in IQVIA Holdings Inc. (NYSE:IQV) by 13.0% in the second quarter, now owning 32,273 shares valued at $5.086 million. Despite this reduction, other institutional investors have significantly increased their positions in IQVIA, with the companyâ€™s stock trading down 1.1% on Friday. Analysts currently rate IQVIA with a "Moderate Buy" and an average price target of $241.44.

**5. IQVIA Holdings Inc. $IQV Shares Bought by Northwestern Mutual Wealth Management Co.**
- Source: MarketBeat | 20251205T080842 | Bullish | Relevance: 100%
- Northwestern Mutual Wealth Management Co. recently increased its stake in IQVIA Holdings Inc. (NYSE:IQV) by 8.2%, now holding 235,487 shares valued at $37.1 million. This comes as IQVIA reported a slight beat on quarterly earnings and revenue and provided optimistic FY2025 guidance. Despite an insider sale, institutional ownership remains high, and analysts maintain a "Moderate Buy" rating for the company.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $265 | $250 | +6% |
| 2025-11-13 | BMO Capital | $260 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | main | Overweight |
| 2025-11-13 | BMO Capital | init | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 5 ($1.46M) |
| Sells | 2 ($4.59M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 11.4% (-0.9%)
- Blackrock Inc.: 8.7% (+4.5%)
- Harris Associates L.: 6.7% (-3.1%)
- State Street Corpora: 4.4% (-1.0%)
- JPMORGAN CHASE & CO: 3.9% (+110.0%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-3.7% 5d) with bearish MACD, trend may be turning.
2. Insider selling cluster: $4.6M in recent transactions.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.96 indicates undervaluation relative to growth. Analyst sentiment positive (1 raises, avg +6%). Insider selling cluster ($4.6M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $38.6B |
| Beta | 1.37 |
| 52W Range | $134.65 - $234.30 |
| Short Interest | 3.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.96 |
| Forward P/E | 17.5 |
| Current P/E | 19.0 |
| YoY Growth | 8.8% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 2.8% to -0.9% (-3.7% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.9pp (needs >4.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 58. Elevated volume (1.5x 20MA), institutional activity likely. OFD pattern: +SLN (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.89% (CS: 47) | Neutral |
| RSI_14 | 58.5 | Neutral |
| MACD Histogram | -0.45 | Bearish |
| vs SMA20 | 1.014x | Above |
| vs SMA50 | 1.058x | Above |
| vs SMA200 | 1.251x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $225.85
- **Stop Loss:** $213.83 (5.3% risk)
- **Target:** $249.89 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 41
- **Position Value:** $9,259.85
- **Portfolio %:** 9.26%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with balanced risk appetite. VIX near 15th percentile of 52-week range signals calm conditions, while modest yield curve steepening (54bps 10Y-3M) suggests healthy growth expectations. Breadth at 52% indicates selective participation rather than broad-based momentum.*

### Earnings

**Next:** 2026-02-05 (Est: $3.40)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.98 | $3.00 | +0.8% |
| 2025Q2 | $2.77 | $2.81 | +1.4% |
| 2025Q1 | $2.63 | $2.70 | +2.6% |
| 2024Q4 | $3.11 | $3.12 | +0.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*